PTC Therapeutics Inc (PTCT) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Total Assets Chart for PTC Therapeutics Inc
PTC Therapeutics Inc (PTCT) total assets for FY2025 were USD 2.9B, a 70.0% change from FY2024. PTC Therapeutics Inc's total assets grew from USD 39.0M in 2004 to USD 2.9B in 2025 (7338.8% over 21 years). Total assets compound annual growth rate: 5-year CAGR of 5.6%, 10-year CAGR of 22.9%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $4.94B
- Implied Share Price
- $59.24
- Enterprise Value
- $3.67B
- Revenue (TTM)
- $1.01B
- EBITDA
- $171.22M
- Profit Margin
- -3.81%
- Trailing P/E
- —
- Forward P/E
- 22.73
- Price/Book (MRQ)
- 1743.27
- Price/Sales (TTM)
- 4.90
- EV/EBITDA
- 21.15
- EV/Revenue
- 3.64
- Dividend Yield
- —
- Book Value
- $-1.99
- Free Cash Flow (FY2025)
- $411.18M
- Free Cash Flow Yield
- 8.32%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.